Drug Trial Radar · NCT07697833
Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
May 15, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- National Institute of Cardiovascular Diseases, PakistanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Horizon Pharmaceuticals
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the effectiveness and safety of Vericiguat with Standard Medical Treatment in Patients with Heart Failure and Reduced Ejection Fraction
Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Vericiguat tabletDrug
Vericiguat 10 mg (titrated from 2.5 mg, to 5 mg, and to 10 mg), on a background of standard of care
PlaceboDrug
Participants will receive a matching placebo tablet. The placebo will follow the same dosing schedule as the study drug (2.5 mg, 5 mg, and 10 mg) to maintain blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quality of life using Kansas City Cardiomyopathy Questionnaire (KCCQ-12)Time frame: Baseline to Month 6
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.